
GENE.01
European humanoid with full-body tactile skin sensing. Features AMD CPUs/GPUs with FPGA edge processors and body-as-compute architecture for low latency.

European humanoid with full-body tactile skin sensing. Features AMD CPUs/GPUs with FPGA edge processors and body-as-compute architecture for low latency.
Generative Bionics' GENE.01 debuted at CES 2026 during AMD's opening keynote, introducing a revolutionary approach to humanoid robotics where intelligence is distributed throughout the body rather than concentrated in a central processor. The Italian startup, based in Genoa, secured $81 million in funding. One of the largest early-stage robotics investments in European history.
GENE.01's defining feature is its full-body tactile skin, a distributed network of touch and force sensors across the robot's entire surface enabling real-time detection of contact, pressure, and micro-interactions. This whole-body tactile sensing, combined with advanced mechatronics and AI, creates a system where the body itself becomes part of the intelligence architecture, inspired by how human locomotion and proprioception emerge from distributed biological systems.
The robot's compute stack emerges from a deep partnership with AMD, who serves as both investor and technology partner. The architecture combines CPUs, GPUs, FPGAs, and embedded processors to fuse tactile, visual, and motion data at high speed, enabling real-time responses that would be impossible with traditional centralized processing.
GENE.01 is the first model in a planned series of humanoid robots from Generative Bionics, with a commercial launch targeted for late 2026. The company aims to move from research to practical deployment in industrial and healthcare sectors where tactile sensitivity and safe human interaction are essential. The name 'GENE' represents the fundamental unit of identity and inheritance, reflecting how this foundational design will evolve into future generations.
Get notified when the price drops
Alerts are stored locally in your browser. Subscribe to our newsletter for additional updates.